Tower View Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$170K Buy
2,811
+26
+0.9% +$1.52K 0.09% 67
2025
Q4
$150K Buy
2,785
+30
+1% +$1.44K 0.07% 65
2025
Q3
$124K Buy
2,755
+31
+1% +$1.45K 0.06% 66
2025
Q2
$126K Sell
2,724
-22
-0.8% -$1.08K 0.07% 74
2025
Q1
$167K Buy
2,746
+22
+0.8% +$1.28K 0.1% 54
2024
Q4
$154K Buy
2,724
+24
+0.9% +$1.34K 0.08% 60
2024
Q3
$140K Buy
2,700
+26
+1% +$1.22K 0.08% 62
2024
Q2
$111K Sell
2,674
-217
-8% -$9.71K 0.06% 65
2024
Q1
$157K Sell
2,891
-175
-6% -$8.91K 0.09% 64
2023
Q4
$157K Sell
3,066
-77
-2% -$4.04K 0.1% 57
2023
Q3
$182K Buy
3,143
+215
+7% +$13.2K 0.13% 56
2023
Q2
$187K Buy
2,928
+16
+0.5% +$1.07K 0.13% 56
2023
Q1
$202K Buy
2,912
+16
+0.6% +$1.13K 0.14% 58
2022
Q4
$208K Buy
2,896
+14
+0.5% +$1.06K 0.14% 60
2022
Q3
$205K Buy
2,882
+14
+0.5% +$1.02K 0.16% 60
2022
Q2
$221K Buy
2,868
+2
+0.1% +$152 0.16% 60
2022
Q1
$209K Sell
2,866
-47
-2% -$3.16K 0.11% 76
2021
Q4
$182K Sell
2,913
-298
-9% -$17.5K 0.09% 80
2021
Q3
$190K Buy
3,211
+2,002
+166% +$132K 0.11% 74
2021
Q2
$81K Buy
1,209
+3
+0.2% +$196 0.04% 90
2021
Q1
$76K Sell
1,206
-437
-27% -$27.2K 0.04% 94
2020
Q4
$102K Buy
1,643
+149
+10% +$9.16K 0.06% 90
2020
Q3
$90K Buy
1,494
+5
+0.3% +$301 0.06% 84
2020
Q2
$88K Buy
1,489
+4
+0.3% +$239 0.06% 76
2020
Q1
$83K Sell
1,485
-401
-21% -$24.5K 0.07% 65
2019
Q4
$121K Buy
1,886
+280
+17% +$16K 0.09% 69
2019
Q3
$81K Sell
1,606
-73
-4% -$3.43K 0.07% 72
2019
Q2
$76K Sell
1,679
-1,620
-49% -$75.5K 0.06% 73
2019
Q1
$157K Buy
3,299
+140
+4% +$6.97K 0.14% 59
2018
Q4
$164K Sell
3,159
-133
-4% -$7.15K 0.17% 58
2018
Q3
$204K Buy
3,292
+13
+0.4% +$771 0.18% 66
2018
Q2
$181K Buy
3,279
+29
+0.9% +$1.57K 0.17% 65
2018
Q1
$206K Buy
3,250
+22
+0.7% +$1.42K 0.21% 64
2017
Q4
$198K Buy
+3,228
New +$202K 0.18% 70

Other funds holding BMY

Tower View Wealth Management's BMY Position: Q1 2026 in Review

Tower View Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 0.93% in Q1 2026, buying an estimated $1.52K and bringing the position to 2,811 shares worth $170K. The position accounts for 0.09% of the portfolio, ranked #67.

Tower View Wealth Management first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. The position peaked at $221K in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Tower View Wealth Management held 2,811 shares of Bristol-Myers Squibb worth $170K as of Q1 2026.
  • Tower View Wealth Management bought 26 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.52K.
  • Bristol-Myers Squibb made up 0.09% of Tower View Wealth Management's portfolio in Q1 2026, its #67 holding.
  • Tower View Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
  • Tower View Wealth Management's Bristol-Myers Squibb position peaked at $221K in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Tower View Wealth Management's 13F filing for Q1 2026, filed 20 Apr 2026.